Curative Biotechnology, Inc. engages in the provision of software solutions for the healthcare market. The company is headquartered in Palm Beach Gardens, Florida and currently employs 4 full-time employees. The company went IPO on 2001-07-11. The firm is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. The company has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology. The company is primarily focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its development pipeline is focused on three therapeutic areas: infectious diseases, oncology, and degenerative eye disease. Under these therapeutic areas, it has targeted three programs: Rabies, Glioblastoma, and Degenerative Eye Diseases. IMT504 is a synthetic immunotherapy to treat late-stage rabies as a stand-alone therapy.
